文献速递妇科

BRCA2定位伴侣蛋白(PALB2)致病性变异与卵巢癌:系统综述与Meta分析

Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis.
PubMed 文献 · Gynecol Oncol · 2023-08-29

该系统综述与Meta分析纳入55项研究、48,194例卵巢癌患者,评估胚系PALB2致病性变异与卵巢癌的关联。在有PALB2测序数据的卵巢癌患者中,0.4%[95%CI 0.3-0.4]携带胚系PALB2致病性变异;20,474例接受胚系检测的卵巢癌患者相对于123,883例对照,携带PALB2致病性变异的合并OR为2.48[95%CI 1.57-3.90]。作者认为需要前瞻性研究评估胚系PALB2致病性变异在卵巢癌发生中的作用。

要点

  • 55项研究、48,194例卵巢癌患者纳入分析,评估胚系PALB2致病性变异与卵巢癌关联。
  • 有PALB2测序数据的卵巢癌患者中0.4%[95%CI 0.3-0.4]携带胚系PALB2致病性变异。
  • 20,474例检测者 vs 123,883例对照,携带PALB2致病性变异的合并OR为2.48[95%CI 1.57-3.90]。

核心结论

  • 卵巢癌人群相对于一般人群携带胚系PALB2致病性变异的合并OR为2.48[95%CI 1.57-3.90]。
  • 作者认为需要前瞻性研究评估胚系PALB2致病性变异在卵巢癌发生中的作用。

研究设计与样本

  • 系统综述与Meta分析,检索主要电子数据库,纳入评估卵巢癌患者多基因panel检测的研究。
  • 共55项研究符合纳入标准,包含48,194例有胚系PALB2致病性变异状态信息的卵巢癌患者。

主要发现

  • 有PALB2测序数据的卵巢癌患者中,0.4%[95%CI 0.3-0.4]携带胚系PALB2致病性变异。
  • 20,474例接受胚系检测的卵巢癌患者相对于123,883例对照,携带PALB2致病性变异的合并OR为2.48[95%CI 1.57-3.90]。

局限性

  • 作者认为需要前瞻性研究评估胚系PALB2致病性变异在卵巢癌发生中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Approximately 20% of ovarian cancers are due to an underlying germline pathogenic variant. While pathogenic variants in several genes have been well-established in the development of hereditary ovarian cancer (e.g. BRCA1/2, RAD51C, RAD51D, BRIP1, mismatch repair genes), the role of partner and localizer of BRCA2 (PALB2) remains uncertain. We sought to utilize meta-analysis to evaluate the association between PALB2 germline pathogenic variants and ovarian cancer. METHODS: We conducted a systematic review and meta-analysis. We searched key electronic databases to identify studies evaluating multigene panel testing in people with ovarian cancer. Eligible trials were subjected to meta-analysis. RESULTS: Fifty-five studies met inclusion criteria, including 48,194 people with ovarian cancer and information available on germline PALB2 pathogenic variant status. Among people with ovarian cancer and available PALB2 sequencing data, 0.4% [95% CI 0.3-0.4] harbored a germline pathogenic variant in the PALB2 gene. The pooled odds ratio (OR) for carrying a PALB2 pathogenic variant among the ovarian cancer population of 20,474 individuals who underwent germline testing was 2.48 [95% CI 1.57-3.90] relative to 123,883 controls. CONCLUSIONS: Our meta-analysis demonstrates that the pooled OR for harboring a PALB2 germline pathogenic variant among people with ovarian cancer compared to the general population is 2.48 [95% CI 1.57-3.90]. Prospective studies evaluating the role of germline PALB2 pathogenic variants in the development of ovarian cancer are warranted.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Narayan P, Ahsan MD, Webster EM, et al. Partner and localizer of BRCA2 (PALB2) pathogenic variants and ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol. 2023. PMID: 37651980. doi:10.1016/j.ygyno.2023.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。